AML patients with IDH1/2 mutations have poor prognosis, generally with low white blood cell counts and high platelet counts, especially when accompanied by other mutations, such as NMP1 and FLT3-ITD. This evidence concerns the gene FLT3 and acute myeloid leukemia.